TITLE

PREVALENCE OF JANUS KINASE 2 MUTATIONS IN PATIENTS WITH UNUSUAL SITE VENOUS THROMBOSIS

AUTHOR(S)
Basquiera, Ana Lisa; Tabares, Aldo H.; Soria, NEstor; Salguero, Miriam; Ryser, Ricardo; Garcia, Juan Jose
PUB. DATE
August 2011
SOURCE
Medicina (Buenos Aires);2011, Vol. 71 Issue 4, p313
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We aimed to study patients with splanchnic vein thrombosis (SVT) and cerebral vein thrombosis (CVT) searching for JAK2 mutations. We evaluated 14 patients (median age: 41.5 years) with portal vein thrombosis (PVT) = 7; mesenteric vein thrombosis (MVT) = 3; and CVT = 4. JAK2 V617F was assessed by allele specific PCR of peripheral blood DNA. In addition, DNA was sequenced for other JAK2 mutations. Other inherited and acquired thrombophilia risk factors were evaluated. JAK2 V617F was positive in four out of seven patients with PVT and in one CVT patient. These five patients had a diagnosis of myeloproliferative disorder (MPD) at the moment of the occurrence of thrombosis (n = 2) or later (n = 2). Patients with MVT and CVT were negative for JAK2 V617F, except one patient with CVT and a diagnosis of essential thrombocythemia. No other JAK2 mutations were found in this cohort. Besides MPD, other thrombophilia risk factors were identified in five patients. One patient had MPD as well as thrombophilia risk factor. In this group, 4 out of 7 of the patients with PVT carried the JAK2 V617F mutation with or without overt MPD. However, the investigation of other JAK2 mutations may not be necessary in patients with thrombosis at unusual sites.
ACCESSION #
70456759

 

Related Articles

  • Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms. Tibes, Raoul; Bogenberger, James M.; Benson, Kasey L.; Mesa, Ruben A. // Molecular Diagnosis & Therapy;Oct2012, Vol. 16 Issue 5, p269 

    Discovery of the JAK2 V617F mutation in the myeloproliferative neoplasms (MPNs) essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) has stimulated great interest in the underlying molecular mechanisms and treatment of these diseases. Along with acceleration of...

  • JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis? Dhiman, Pratibha; Saxena, Priyanka // Case Reports in Hematology;3/24/2015, Vol. 2015, p1 

    Splanchnic venous thrombosis (SVT) includes thrombosis of the hepatic, portal, and mesenteric venous system. Myeloproliferative neoplasms (MPNs) are important factors of SVT in adults. Addition of JAK2V617F mutation in WHO criteria for diagnosis of MPNs has made this test a useful tool for...

  • Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Chen, Chih-Cheng; Gau, Jyh-Pyng; Chou, Hui-Ju; You, Jie-Yu; Huang, Cih-En; Chen, Yi-Yang; Lung, Jrhau; Chou, Yi-Sheng; Leu, Yu-Wei; Lu, Chang-Hsien; Lee, Kuan-Der; Tsai, Ying-Huang // Annals of Hematology;Dec2014, Vol. 93 Issue 12, p2029 

    Calreticulin ( CALR) mutations were recently identified in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) devoid of JAK2 and MPL mutations. We evaluated the clinical, laboratory, and molecular features of a Taiwanese population of patients with ET. Among 147 ET...

  • Thrombosis in myeloprol iferative disorders: pathogenetic facts and speculation. Landolfi, R.; Di Gennaro, L.; Falanga, A. // Leukemia (08876924);Dec2008 Supplement, Vol. 22, pP142 

    Thrombophilia, which severely impacts on morbidity and mortality of polycythaemia vera and essential thrombocythaemia, is variably characterized by microcirculatory disturbances, arterial and venous thromboses that often precede disease recognition. Thus, the search for Janus Kinase 2 mutation,...

  • Current Treatment Concepts of Philadelphia-Negative MPN. Wolf, D.; Rudzki, J.; Gastl, G. // Current Cancer Drug Targets;Jan2011, Vol. 11 Issue 1, p44 

    No abstract available.

  • TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Martínez-Avilés, Luz; Besses, Carlos; Álvarez-Larrán, Alberto; Torres, Erica; Serrano, Sergi; Bellosillo, Beatriz // Annals of Hematology;Apr2012, Vol. 91 Issue 4, p533 

    Mutations in the TET2 and ASXL1 genes have been described in approximately 14% and 8% of patients, respectively, with classic myeloproliferative neoplasms (MPN), but their role as possible new diagnostic molecular markers is still inconclusive. In addition, other genes such as IDH1, IDH2, and...

  • Melting Point Assay for the JAK2 V617F Mutation, Comparison with Amplification Refractory Mutation System (ARMS) in Diagnostic Samples, and Implications for Daily Routine. Ochsenreither, Sebastian; Reinwald, Mark; Thiel, Eckhard; Burmeister, Thomas // Molecular Diagnosis & Therapy;Jun2010, Vol. 14 Issue 3, p185 

    Background: Reliable detection of the JAK2 V617F mutation is a major criterion in the diagnosis of BCR/ABL-negative myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. A multitude of methods has been applied to both qualitative and...

  • Coexistencia de las mutaciones V617F del gen JAK-2 y G20210A del gen de la protrombina. Velarde Félix, Jesús Salvador; Llamas, Ramón Rivas; Morales, Lourdes Zazueta; Ochoa Ramírez, Luis Antonio; Ríos Tostado, Juan José; Aguilar, Horacio Rendón // Revista Mexicana de Patologia Clinica;jul-sep2008, Vol. 55 Issue 3, p139 

    Introduction: The JAK-2 V617F mutation has great importance in the diagnosis, classification and treatment of chronic myeloproliferative disorders. Clinical case: In a 64 year old woman thrombocytosis was detected in the preoperative analyses for blepharoplastia who developed cerebral-vascular...

  • Calreticulin Mutations in Myeloproliferative Neoplasms: Comparison of Three Diagnostic Methods. Park, Ji-Hye; Sevin, Margaux; Ramla, Selim; Truffot, Aurélie; Verrier, Tiffany; Bouchot, Dominique; Courtois, Martine; Bas, Mathilde; Benali, Sonia; Bailly, François; Favre, Bernardine; Guy, Julien; Martin, Laurent; Maynadié, Marc; Carillo, Serge; Girodon, François // PLoS ONE;10/26/2015, Vol. 10 Issue 10, p1 

    Calreticulin (CALR) mutations have recently been reported in 70–84% of JAK2V617F-negative myeloproliferative neoplasms (MPN), and this detection has become necessary to improve the diagnosis of MPN. In a large single-centre cohort of 298 patients suffering from Essential Thrombocythemia...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics